Prokaryotic Translation: Processes, Structure, and Regulation

Prokaryotic translation is the process by which bacterial ribosomes read messenger RNA and assemble proteins, amino acid by amino acid. It shares a basic logic with the same process in human cells, but the machinery differs enough that most antibiotics exploit the gap. Bacteria pull off something eukaryotic cells cannot: they begin translating an mRNA while it is still being transcribed, physically coupling the two machines into a single complex. That tight coordination, along with a suite of quality-control and regulatory systems, makes bacterial translation faster, more streamlined, and in some ways more precarious than its counterpart in larger organisms.

The Bacterial Ribosome

Bacterial ribosomes are smaller than those found in eukaryotic cells. The complete particle, called the 70S ribosome, is built from two unequal halves: a small 30S subunit and a large 50S subunit. The small subunit’s main job is decoding, matching each three-letter codon on the mRNA to the right transfer RNA. The large subunit is where new peptide bonds are actually formed. Crystal structures of the intact E. coli ribosome resolved to 3.5 ångströms gave researchers their first detailed look at how the two subunits lock together and how the peptide-forming active site is arranged when both halves are present.¹

Not every bacterial ribosome looks exactly the same. Comparisons between species reveal structural diversity around a conserved core. In Mycobacterium smegmatis, for instance, the 70S ribosome carries extra RNA segments that form additional features on the surface, including a conspicuous rod-like protrusion nicknamed the “steeple” on the large subunit, traced to an extra RNA helix called H54a.² These species-specific differences matter because they can affect how antibiotics bind, and they remind us that the textbook picture of the ribosome is drawn largely from a single organism.

Starting Up: Translation Initiation

Translation in bacteria begins when the small 30S subunit, three initiation factors (IF1, IF2, and IF3), an mRNA, and a special initiator tRNA carrying formylmethionine all come together. This first assembly is unstable, called a 30S pre-initiation complex. A rearrangement then locks the start codon and the initiator tRNA’s anticodon together in the ribosome’s P site, producing a stable 30S initiation complex. Only then does the large 50S subunit join, forming the full 70S ribosome ready for elongation.³

A key signal that positions the mRNA correctly on the small subunit is the Shine-Dalgarno sequence, a short stretch of nucleotides upstream of the start codon that base-pairs with a complementary region near the end of 16S ribosomal RNA. Structural work at 3.3 ångströms showed that the resulting short double helix sits in a protected chamber between the head and platform domains of the 30S subunit, snugly docked among ribosomal RNA helices and several ribosomal proteins.⁴ This interaction is so important that strengthening it experimentally can compensate for mutations in the initiator tRNA that would otherwise be lethal.⁵

Elongation and Peptide Bond Formation

Once the full 70S ribosome is assembled, the elongation cycle repeats hundreds or thousands of times to build the protein. Each cycle has three broad steps: delivering a new aminoacyl-tRNA to the ribosome’s A site, forming the peptide bond, and moving everything forward by one codon.

Delivery is handled by elongation factor Tu (EF-Tu), which arrives bound to GTP and carrying an aminoacyl-tRNA. When the tRNA’s anticodon correctly pairs with the codon exposed in the A site, structural changes in the small subunit shift the 30S shoulder inward, bringing EF-Tu close to a critical element on the large subunit called the sarcin-ricin loop. That contact positions a conserved histidine residue in EF-Tu to trigger GTP hydrolysis. Once GTP is split, EF-Tu changes shape, releases the tRNA, and peels away domain by domain.⁶ This multi-step checking process is how the ribosome achieves proofreading: an incorrect tRNA is more likely to fall off before GTP hydrolysis commits the ribosome to using it.

The peptide bond itself is formed at the peptidyl transferase center on the large subunit, and the finding that transformed the field is that this active site is made entirely of RNA, not protein. Crystallographic structures confirmed that peptidyl transferase is an RNA enzyme, a ribozyme.⁷ Among all the RNA components at this site, one chemical group stands out: the 2′-hydroxyl on the ribose sugar of nucleotide A2451 in 23S ribosomal RNA. Replacing that single hydroxyl with hydrogen nearly eliminates catalytic activity, even when the rest of the active site is intact.⁸ The same residue, along with nearby G2447, was identified from the first atomic-resolution structure of the large subunit as a likely participant in catalysis.⁹

Translocation

After each peptide bond forms, the tRNAs and mRNA need to shift by exactly one codon so the next round can begin. This happens in two stages. First, the acceptor ends of the tRNAs (the parts touching the large subunit) swing into their next positions while their anticodon ends stay put on the small subunit, creating so-called hybrid states.¹⁰ Then elongation factor G (EF-G), another GTPase, catalyzes the second half of the movement: the mRNA and tRNA anticodon ends shift relative to the small subunit, completing translocation. Crystal structures of EF-G on the ribosome in different rotation states showed that EF-G binding stabilizes an intermediate rotated conformation of the two subunits, and GTP hydrolysis allows it to relax, ratcheting the ribosome forward.¹¹

Termination and Recycling

When a stop codon enters the A site, no tRNA recognizes it. Instead, protein release factors step in. Bacteria use two class 1 release factors: RF1 recognizes UAA and UAG, while RF2 recognizes UAA and UGA. Both trigger hydrolysis of the bond connecting the finished protein to the last tRNA, freeing the polypeptide.¹² Crystal structures of both factors bound to cognate stop codons on a Thermus thermophilus ribosome revealed the details of how they reach into the decoding center and the peptidyl transferase center simultaneously.¹³ A third factor, RF3, accelerates the departure of RF1 or RF2 after the protein has been released.

The ribosome does not simply fall apart afterward. It needs active disassembly, called ribosome recycling, to free the subunits for another round. Ribosome recycling factor (RRF) and EF-G work together in a GTP-dependent reaction to split the 70S ribosome. The model based on structural data is that EF-G binding triggers a rotation within RRF that destabilizes critical bridges holding the two subunits together.¹⁴ A 3.5 ångström crystal structure of the post-termination 70S complex with EF-G, RRF, and two tRNAs revealed that the deacylated tRNA in the P site shifts into a previously unseen binding state that actively contributes to subunit separation by making unfavorable contacts with the large subunit.¹⁵

The Expressome and Transcription-Translation Coupling

Because bacteria lack a nuclear membrane, the ribosome can latch onto an mRNA while RNA polymerase (RNAP) is still making it. The physical complex of RNAP and the lead ribosome is called the expressome. Cryo-electron microscopy showed that in E. coli, the expressome continuously shields about 30 nucleotides of mRNA stretching from the polymerase active site to the ribosome decoding center.¹⁶

The connection between the two machines is not just accidental proximity. The transcription factor NusG can bridge the ribosome and RNAP directly, stabilizing the interface.¹⁷ Work done inside living cells using cryo-electron tomography confirmed that the expressome also includes the elongation factors NusA and NusG. Inhibiting translation caused the complex to fall apart, while inhibiting transcription stalled and rearranged it, indicating that both machines need to be actively running for the coupling to persist.¹⁸

Coupling matters for gene regulation. When the ribosome keeps pace with RNAP, it prevents the formation of RNA secondary structures behind the polymerase that might cause premature transcription termination (a phenomenon called Rho-dependent termination). If the ribosome falls behind or stalls, regulatory consequences follow.

Rescuing Stalled Ribosomes

Ribosomes sometimes stall mid-translation, for example when an mRNA is broken and has no stop codon. Bacteria have a clever rescue system built around a hybrid molecule called transfer-messenger RNA (tmRNA). During rescue, tmRNA first acts as a tRNA to enter the stalled ribosome, then switches to acting as an mRNA, directing the ribosome to add a short peptide tag to the end of the incomplete protein. That tag marks the unfinished protein for destruction by cellular proteases, the problematic mRNA is degraded, and the stalled ribosome is freed.¹⁹ tmRNA works together with a small partner protein called SmpB, whose synergistic interaction is essential for rescue to proceed.²⁰

tmRNA is not the only backup. An alternative rescue factor called ArfB can also free stalled ribosomes, and it adapts its behavior depending on how much mRNA is sticking out past the stall site. When the leftover mRNA is short, ArfB works as a single molecule fitting into the A site. When the mRNA is longer, ArfB forms a pair that displaces the mRNA by more than 20 ångströms and tucks it into the space between the subunits.²¹ Having multiple rescue pathways underscores how dangerous a stalled ribosome is: it ties up one of the cell’s most expensive machines and can produce toxic protein fragments.

Regulatory Layers That Control Translation

Bacteria regulate translation at multiple levels. One of the broadest responses occurs during nutrient starvation, when cells accumulate signaling molecules called (p)ppGpp in what is known as the stringent response. These alarmones bind directly to RNA polymerase (with help from the protein DksA) and reprogram transcription of hundreds of genes, downregulating ribosomal RNA and ribosomal protein genes while upregulating amino acid biosynthesis. The stringent response also inhibits translation initiation and elongation, effectively putting the central dogma on pause so the cell can survive the stress.²²

At the level of individual mRNAs, riboswitches provide gene-specific control. These are structured RNA elements embedded in the mRNA itself, typically in the region upstream of the coding sequence. When a riboswitch binds its target small molecule, it changes shape and can block access to the Shine-Dalgarno sequence, preventing the ribosome from initiating. Single-molecule experiments showed that an mRNA hosting a riboswitch alternates between states of high and low Shine-Dalgarno accessibility, and adding the riboswitch ligand shortens the high-accessibility bursts while lengthening the gaps between them.²³

Small noncoding RNAs (sRNAs) add yet another regulatory dimension. These short RNA molecules, often assisted by the chaperone protein Hfq, base-pair with target mRNAs to either promote or block translation. For example, several sRNAs activate translation of the stress-response gene rpoS by pairing with the mRNA leader, with Hfq recruited to upstream sequence motifs to help anneal the sRNA to its target.²⁴ In other cases, sRNAs recruit Hfq to a site on the mRNA where it directly interferes with translation, as seen with regulation of the sugar transporter gene manX.²⁵

Programmed Frameshifting

Sometimes bacteria deliberately break the reading frame. In programmed −1 frameshifting, the ribosome slips backward by one nucleotide on a specific “slippery” mRNA sequence, usually because a folded RNA structure downstream stalls forward movement and traps the ribosome in a metastable state.²⁶ The result is a fusion protein whose C-terminal half comes from a different reading frame than its N-terminal half. Bacteria use this trick to regulate expression of certain genes, including components of mobile genetic elements and even a release factor gene.

Frameshifting turns out to be sensitive to ribosome traffic. On heavily translated mRNAs carrying frameshift motifs, collisions between a stalled ribosome and the one behind it can alter the frequency of frameshifting in both the leading and trailing ribosomes.²⁷ This means the cell’s overall translational load can feed back into the regulation of specific genes that rely on frameshifting.

Co-translational Protein Folding

Proteins do not wait until they are fully made to start folding. As the growing polypeptide emerges from the ribosome’s exit tunnel on the large subunit, it encounters trigger factor (TF), the first chaperone in the bacterial folding pathway. TF binds near the tunnel exit through its N-terminal domain and creates a sheltered space where early folding can happen without the risk of the new chain sticking to other proteins.²⁸ Structural studies showed that contact with ribosomal protein L29 triggers a conformational change in TF, exposing hydrophobic patches toward the tunnel opening. These patches compete with other hydrophobic surfaces in the crowded cytoplasm for contact with the emerging chain, preventing aggregation and giving the protein its best chance at reaching the correct shape.²⁹

Leaderless mRNAs

Most bacterial mRNAs carry a 5′ untranslated region that includes a Shine-Dalgarno sequence, but a significant minority do not. These leaderless mRNAs start directly with the AUG start codon and lack the usual ribosome-recruiting signal. Their translation must rely on molecular strategies distinct from the standard Shine-Dalgarno-dependent pathway.³⁰ Current evidence points to a role for intact 70S ribosomes, rather than free 30S subunits, in recognizing leaderless mRNAs directly. This alternative initiation route is found across diverse bacterial lineages and is particularly common in certain archaea as well, hinting that it may represent an ancient mode of translation that predates the Shine-Dalgarno system.

Speed, Accuracy, and Energetic Trade-offs

Bacterial translation is fast, with E. coli ribosomes adding roughly 15 to 20 amino acids per second under optimal growth conditions. Evolutionary analysis suggests the translational machinery has been optimized toward high speed at some cost to accuracy.³¹ The error rate for incorporating the wrong amino acid is roughly one in a few thousand, which is tolerable for most proteins but not negligible when you consider that a bacterium in exponential growth may be running tens of thousands of ribosomes at once.

Ribosomes are also among the most expensive machines a cell builds, consuming a large share of its energy and raw materials. Cellular ATP requirements constrain how much a cell can invest in boosting translation capacity. For non-native protein sequences (as in biotechnology applications), optimizing the supply of the right tRNAs can be a more economical strategy than simply building more ribosomes.³²

RNA Modifications and Antibiotic Vulnerability

Both ribosomal RNA and tRNAs carry chemical modifications, methyl groups, pseudouridines, and other additions placed after transcription. Many of these modifications were long considered nonessential under normal lab conditions, but recent work revealed that they become important during antibiotic stress. Knocking out specific tRNA and rRNA modification genes altered how E. coli responded to sub-lethal doses of antibiotics from several different families, including aminoglycosides, fluoroquinolones, beta-lactams, chloramphenicol, and trimethoprim.³³ The implication is that fine-tuning of codon decoding through RNA modifications gives bacteria a previously underappreciated way to respond to chemical threats.

Antibiotics that target the ribosome exploit its RNA-rich active sites. Structural studies of the antibiotic thermorubin, for instance, showed that it binds at the interface between the subunits near the A site, yet an aminoacyl-tRNA can still fully accommodate alongside it by causing a nucleotide to swing out of the way. The antibiotic inhibits translation not by physically blocking tRNA entry but through a subtler mechanism that disrupts normal ribosome dynamics.³⁴ Understanding these mechanisms at atomic resolution is central to designing new antibiotics, particularly as resistance continues to erode the effectiveness of existing drugs.